Paolo Tarantino/X
Jan 29, 2025, 22:05
Paolo Tarantino: Terrific 2 weeks for breast oncology
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on X:
“What a terrific 2 weeks for breast oncology:
- Dato-DXd approved for HR+/HER2- mBC
- T-DXd approval expanded to HER2-ultralow disease
- inavolisib triplet announced to prolong OS
And I can bet that some more practice changing data is being submitted to ASCO25 before midnight.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 28, 2025, 18:34
Feb 28, 2025, 15:34
Feb 28, 2025, 15:33
Feb 28, 2025, 15:25
Feb 28, 2025, 15:22
Feb 28, 2025, 15:20
Feb 28, 2025, 15:13
Feb 28, 2025, 15:02
Feb 28, 2025, 14:43
Feb 28, 2025, 14:37